{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T00:16:14Z","timestamp":1771632974430,"version":"3.50.1"},"reference-count":157,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,20]],"date-time":"2024-08-20T00:00:00Z","timestamp":1724112000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Ministry of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.critrevonc.2024.104481","type":"journal-article","created":{"date-parts":[[2024,8,17]],"date-time":"2024-08-17T22:42:26Z","timestamp":1723934546000},"page":"104481","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Unleashing precision: A review of targeted approaches in pleural mesothelioma"],"prefix":"10.1016","volume":"203","author":[{"given":"Mario","family":"Occhipinti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1148-7056","authenticated-orcid":false,"given":"Marta","family":"Brambilla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raimondo","family":"Di Liello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Ambrosini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorenzo","family":"Lobianco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rita","family":"Leporati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Salvarezza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabiana","family":"Vitiello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Marchesi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Manglaviti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teresa","family":"Beninato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Mazzeo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Proto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arsela","family":"Prelaj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Ferrara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carminia Maria","family":"Della Corte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Lo Russo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Filippo","family":"de Braud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monica","family":"Ganzinelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Viscardi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2024.104481_bib1","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/s00262-008-0582-6","article-title":"Treatment of ovarian cancer cell lines with 5-aza-2\u2019-deoxycytidine upregulates the expression of cancer-testis antigens and class I major histocompatibility complex-encoded molecules","volume":"58","author":"Adair","year":"2009","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.critrevonc.2024.104481_bib2","doi-asserted-by":"crossref","first-page":"e141","DOI":"10.1016\/j.jtho.2017.04.028","article-title":"Malignant pleural mesothelioma harboring both G719C and S768I mutations of EGFR successfully treated with Afatinib","volume":"12","author":"Agatsuma","year":"2017","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.critrevonc.2024.104481_bib3","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.1158\/1535-7163.MCT-14-0132","article-title":"Efficacy of RG7787, a next-generation mesothelin-targeted immunotoxin, against triple-negative breast and gastric cancers","volume":"13","author":"Alewine","year":"2014","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.critrevonc.2024.104481_bib4","doi-asserted-by":"crossref","unstructured":"E. Aliagas, A. Alay, M. Mart\u00ednez-Iniesta, M. Hern\u00e1ndez-Madrigal, D. Cordero, M. Gausachs, E. Pros, M. Saig\u00ed, S. Busacca, A.J. Sharkley, A. Dawson, R. Palmero, S. Padrones, S. Aso, I. Escobar, R. Ramos, R. Llatj\u00f3s, A. Vidal, M. Varela, M. S\u00e1nchez-C\u00e9spedes, D. Fennell, C. Mu\u00f1oz-Pinedo, A. Villanueva, X. Sol\u00e9, E. Nadal, Efficacy of CDK4\/6 inhibitors in preclinical models of malignant pleural mesothelioma, BioRxiv (2021) 2021.02.08.430196. \u3008https:\/\/doi.org\/10.1101\/2021.02.08.430196\u3009.","DOI":"10.1101\/2021.02.08.430196"},{"key":"10.1016\/j.critrevonc.2024.104481_bib5","unstructured":"Anon, APG-2449 in Patients With Advanced Solid Tumors - Full Text View - ClinicalTrials.gov, (n.d.). \u3008https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03917043\u3009 (accessed December 11, 2022)."},{"key":"10.1016\/j.critrevonc.2024.104481_bib6","unstructured":"Anon, CAR T Cells in Mesothelin Expressing Cancers - Full Text View - ClinicalTrials.gov, (n.d.). \u3008https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03054298\u3009 (Accessed May 28, 2023)."},{"key":"10.1016\/j.critrevonc.2024.104481_bib7","unstructured":"Anon, Pevonedistat Alone and in Combination With Chemotherapy in Patients With Mesothelioma - Full Text View - ClinicalTrials.gov, (n.d.). \u3008https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03319537\u3009 (accessed December 11, 2022)."},{"key":"10.1016\/j.critrevonc.2024.104481_bib8","unstructured":"Anon, \u03b1PD1-MSLN-CAR T Cells for the Treatment of MSLN-positive Advanced Solid Tumors - Full Text View - ClinicalTrials.gov, (n.d.). \u3008https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04489862\u3009 (Accessed May 28, 2023)."},{"key":"10.1016\/j.critrevonc.2024.104481_bib9","unstructured":"Anon, Phase 1\/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer - Full Text View - ClinicalTrials.gov, (n.d.). \u3008https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03907852\u3009 (Accessed May 28, 2023)."},{"key":"10.1016\/j.critrevonc.2024.104481_bib10","unstructured":"Anon, A Phase 1 Dose Escalation Study of VS-5584 Administered in Combination With VS-6063, in Subjects With Relapsed Malignant Mesothelioma - Full Text View - ClinicalTrials.gov, (n.d.). \u3008https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02372227?cond=mesothelioma&draw=3&rank=196\u3009 (accessed December 11, 2022)."},{"key":"10.1016\/j.critrevonc.2024.104481_bib11","unstructured":"Anon, Mesothelioma Stratified Therapy (MiST): A Multi-drug Phase II Trial in Malignant Mesothelioma - Full Text View - ClinicalTrials.gov, (n.d.). \u3008https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03654833\u3009 (Accessed May 28, 2023)."},{"key":"10.1016\/j.critrevonc.2024.104481_bib12","unstructured":"Anon, APembrolizumab + Defactinib In Pleural Mesothelioma - Full Text View - ClinicalTrials.gov, (n.d.). \u3008https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04201145\u3009 (Accessed December 11, 2022)."},{"key":"10.1016\/j.critrevonc.2024.104481_bib13","unstructured":"Anon, Everolimus (RAD001) for the Treatment of Malignant Pleural Mesothelioma With Merlin\/NF2 Loss as a Biomarker to Predict Sensitivity - Study Results - ClinicalTrials.gov, (n.d.). \u3008https:\/\/clinicaltrials.gov\/ct2\/show\/results\/NCT01024946?view=results\u3009 (Accessed December 11, 2022)."},{"key":"10.1016\/j.critrevonc.2024.104481_bib14","unstructured":"Anon, A Phase 1\/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer - Full Text View - ClinicalTrials.gov, (n.d.). \u3008https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05451849\u3009 (Accessed May 28, 2023)."},{"key":"10.1016\/j.critrevonc.2024.104481_bib15","unstructured":"Anon, A Phase I Study of IAG933 in Patients With Advanced Mesothelioma and Other Solid Tumors - Full Text View - ClinicalTrials.gov, (n.d.). \u3008https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04857372?cond=mesothelioma&draw=2&rank=8\u3009 (Accessed December 11, 2022)."},{"key":"10.1016\/j.critrevonc.2024.104481_bib16","unstructured":"Anon, Oral TEAD Inhibitor Targeting the Hippo Pathway in Subjects With Advanced Solid Tumors - Full Text View - ClinicalTrials.gov, (n.d.). \u3008https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05228015\u3009 (Accessed December 11, 2022)."},{"key":"10.1016\/j.critrevonc.2024.104481_bib17","unstructured":"Anon, First-in-class, first-in-human phase 1 trial of VT3989, an inhibitor of yes-associated protein (YAP)\/transcriptional enhancer activator domain (TEAD), in patients (pts) with advanced solid tumors enriched for malignant mesothelioma and other tumors with neurofibromatosis 2 (NF2) mutations, (n.d.). \u3008https:\/\/www.abstractsonline.com\/pp8\/#!\/10828\/presentation\/10247\u3009 (Accessed May 28, 2023)."},{"key":"10.1016\/j.critrevonc.2024.104481_bib18","unstructured":"Anon, Intratumor Injection of Anti-Mesothelin Immunotoxin LMB-100 With Ipilimumab in Malignant Mesothelioma - Full Text View - ClinicalTrials.gov, (n.d.). \u3008https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT04840615\u3009 (accessed May 28, 2023)."},{"key":"10.1016\/j.critrevonc.2024.104481_bib19","unstructured":"Anon, SS1P and Pentostatin Plus Cyclophosphamide for Mesothelioma - Study Results - ClinicalTrials.gov, (n.d.). \u3008https:\/\/classic.clinicaltrials.gov\/ct2\/show\/results\/NCT01362790\u3009 (Accessed February 11, 2024)."},{"key":"10.1016\/j.critrevonc.2024.104481_bib20","unstructured":"Anon, BEAT-meso: Bevacizumab and Atezolizumab in Malignant Pleural Mesothelioma - Full Text View - ClinicalTrials.gov, (n.d.). \u3008https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03762018\u3009 (Accessed May 26, 2023)."},{"key":"10.1016\/j.critrevonc.2024.104481_bib21","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1016\/j.jtho.2018.07.015","article-title":"Mismatch repair protein defects and microsatellite instability in malignant pleural mesothelioma","volume":"13","author":"Arulananda","year":"2018","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.critrevonc.2024.104481_bib22","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0140-6736(20)32714-8","article-title":"First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial","volume":"397","author":"Baas","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2024.104481_bib23","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.mrfmmm.2011.01.001","article-title":"XRCC1 and ERCC1 variants modify malignant mesothelioma risk: a case-control study","volume":"708","author":"Betti","year":"2011","journal-title":"Mutat. Res"},{"key":"10.1016\/j.critrevonc.2024.104481_bib24","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1097\/JTO.0000000000000055","article-title":"PI3K\/mTOR signaling in mesothelioma patients treated with induction chemotherapy followed by extrapleural pneumonectomy","volume":"9","author":"Bitanihirwe","year":"2014","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.critrevonc.2024.104481_bib25","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.devcel.2012.03.013","article-title":"Growth control by committee: intercellular junctions, cell polarity, and the cytoskeleton regulate Hippo signaling","volume":"22","author":"Boggiano","year":"2012","journal-title":"Dev. Cell"},{"key":"10.1016\/j.critrevonc.2024.104481_bib26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.anndiagpath.2016.04.007","article-title":"c-Met expression and MET amplification in malignant pleural mesothelioma","volume":"23","author":"Bois","year":"2016","journal-title":"Ann. Diagn. Pathol."},{"key":"10.1016\/j.critrevonc.2024.104481_bib27","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.neo.2017.05.003","article-title":"Combined Inhibition of CDK4\/6 and PI3K\/AKT\/mTOR pathways induces a synergistic anti-tumor effect in malignant pleural mesothelioma cells","volume":"19","author":"Bonelli","year":"2017","journal-title":"Neoplasia"},{"key":"10.1016\/j.critrevonc.2024.104481_bib28","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/ng.3520","article-title":"Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations","volume":"48","author":"Bueno","year":"2016","journal-title":"Nat. Genet"},{"key":"10.1016\/j.critrevonc.2024.104481_bib29","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/ng.3520","article-title":"Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations","volume":"48","author":"Bueno","year":"2016","journal-title":"Nat. Genet"},{"key":"10.1016\/j.critrevonc.2024.104481_bib30","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/S1470-2045(13)70125-6","article-title":"Thalidomide versus active supportive care for maintenance in patients with malignant mesothelioma after first-line chemotherapy (NVALT 5): an open-label, multicentre, randomised phase 3 study","volume":"14","author":"Buikhuisen","year":"2013","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2024.104481_bib31","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.semcancer.2012.03.003","article-title":"The role of classical and non-classical HLA class I antigens in human tumors","volume":"22","author":"Bukur","year":"2012","journal-title":"Semin Cancer Biol."},{"key":"10.1016\/j.critrevonc.2024.104481_bib32","doi-asserted-by":"crossref","first-page":"5869","DOI":"10.1038\/onc.2008.273","article-title":"HLA antigen changes in malignant cells: epigenetic mechanisms and biologic significance","volume":"27","author":"Campoli","year":"2008","journal-title":"Oncogene"},{"key":"10.1016\/j.critrevonc.2024.104481_bib33","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.lungcan.2013.11.026","article-title":"A systematic review and meta-analysis of surgical treatments for malignant pleural mesothelioma","volume":"83","author":"Cao","year":"2014","journal-title":"Lung Cancer"},{"key":"10.1016\/j.critrevonc.2024.104481_bib34","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","article-title":"The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data","volume":"2","author":"Cerami","year":"2012","journal-title":"Cancer Discov."},{"key":"10.1016\/j.critrevonc.2024.104481_bib35","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1016\/j.bbamcr.2018.07.013","article-title":"Novel nuclear translocation of inositol polyphosphate 4-phosphatase is associated with cell cycle, proliferation and survival","volume":"1865","author":"Chaudhuri","year":"2018","journal-title":"Biochim Biophys. Acta Mol. Cell Res"},{"key":"10.1016\/j.critrevonc.2024.104481_bib36","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1080\/17425247.2019.1598374","article-title":"Epidermal growth factor receptor (EGFR)-targeted therapies in mesothelioma","volume":"16","author":"Chia","year":"2019","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.critrevonc.2024.104481_bib37","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1158\/0008-5472.CAN-15-2125","article-title":"Combining epigenetic and immunotherapy to combat cancer","volume":"76","author":"Chiappinelli","year":"2016","journal-title":"Cancer Res"},{"key":"10.1016\/j.critrevonc.2024.104481_bib38","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1073\/pnas.95.2.669","article-title":"Isolation of a high-affinity stable single-chain Fv specific for mesothelin from DNA-immunized mice by phage display and construction of a recombinant immunotoxin with anti-tumor\u202factivity","volume":"95","author":"Chowdhury","year":"1998","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.critrevonc.2024.104481_bib39","doi-asserted-by":"crossref","unstructured":"B.C. Christensen, E.A. Houseman, J.J. Godleski, C.J. Marsit, J.L. Longacker, C.R. Roelofs, M.R. Karagas, M.R. Wrensch, R.-F. Yeh, H.H. Nelson, J.L. Wiemels, S. Zheng, J.K. Wiencke, R. Bueno, D.J. Sugarbaker, K.T. Kelsey, Epigenetic Profiles Distinguish Pleural Mesothelioma from Normal Pleura and Predict Lung Asbestos Burden and Clinical Outcome, (n.d.). https:\/\/doi.org\/10.1158\/0008-5472.CAN-08-2586.","DOI":"10.1158\/0008-5472.CAN-08-2586"},{"key":"10.1016\/j.critrevonc.2024.104481_bib40","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1038\/nature04117","article-title":"Vertebrate Smoothened functions at the primary cilium","volume":"437","author":"Corbit","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2024.104481_bib41","doi-asserted-by":"crossref","first-page":"OF1","DOI":"10.1158\/2159-8290.CD-22-0886","article-title":"Genomic instability and protumoral inflammation are associated with primary resistance to anti-PD-1 + antiangiogenesis in malignant pleural mesothelioma","volume":"13","author":"Danlos","year":"2023","journal-title":"Cancer Discov."},{"key":"10.1016\/j.critrevonc.2024.104481_bib42","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.lungcan.2007.08.035","article-title":"Gene methylation in pleural mesothelioma: Correlations with clinico-pathological features and patient\u2019s follow-up","volume":"59","author":"Destro","year":"2008","journal-title":"Lung Cancer"},{"key":"10.1016\/j.critrevonc.2024.104481_bib43","doi-asserted-by":"crossref","first-page":"4398","DOI":"10.1242\/dev.098079","article-title":"Derivation of lung mesenchymal lineages from the fetal mesothelium requires hedgehog signaling for mesothelial cell entry","volume":"140","author":"Dixit","year":"2013","journal-title":"Development"},{"key":"10.1016\/j.critrevonc.2024.104481_bib44","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1016\/S1470-2045(23)00446-1","article-title":"Pembrolizumab plus lenvatinib in second-line and third-line patients with pleural mesothelioma (PEMMELA): a single-arm phase 2 study","volume":"24","author":"Douma","year":"2023","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2024.104481_bib45","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.molimm.2017.04.012","article-title":"Epigenetics and immunotherapy: the current state of play","volume":"87","author":"Dunn","year":"2017","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.critrevonc.2024.104481_bib46","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2015.124","article-title":"Inhibition of autophagy sensitizes malignant pleural mesothelioma cells to dual PI3K\/mTOR inhibitors","volume":"6","author":"Echeverry","year":"2015","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.critrevonc.2024.104481_bib47","doi-asserted-by":"crossref","first-page":"500","DOI":"10.3390\/genes6030500","article-title":"Hedgehog signaling in malignant pleural mesothelioma","volume":"6","author":"Felley-Bosco","year":"2015","journal-title":"Genes (Basel)"},{"key":"10.1016\/j.critrevonc.2024.104481_bib48","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1200\/JCO.2018.79.0543","article-title":"Maintenance defactinib versus placebo after first-line chemotherapy in patients with merlin-stratified pleural mesothelioma: COMMAND-A Double-blind, randomized, Phase II study","volume":"37","author":"Fennell","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2024.104481_bib49","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/S2213-2600(20)30390-8","article-title":"Rucaparib in patients with BAP1-deficient or BRCA1-deficient mesothelioma (MiST1): an open-label, single-arm, phase 2a clinical trial","volume":"9","author":"Fennell","year":"2021","journal-title":"Lancet Respir. Med"},{"key":"10.1016\/j.critrevonc.2024.104481_bib50","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/S1470-2045(22)00062-6","article-title":"Abemaciclib in patients with p16ink4A-deficient mesothelioma (MiST2): a single-arm, open-label, phase 2 trial","volume":"23","author":"Fennell","year":"2022","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2024.104481_bib51","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.lungcan.2006.06.017","article-title":"Promoter methylation of RASSF1A, RAR\u03b2 and DAPK predict poor prognosis of patients with malignant mesothelioma","volume":"54","author":"Fischer","year":"2006","journal-title":"Lung Cancer"},{"key":"10.1016\/j.critrevonc.2024.104481_bib52","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.resinv.2013.02.002","article-title":"Hyaluronic acid in the pleural fluid of patients with malignant pleural mesothelioma","volume":"51","author":"Fujimoto","year":"2013","journal-title":"Respir. Invest."},{"issue":"17","key":"10.1016\/j.critrevonc.2024.104481_bib53","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15174309","article-title":"Epithelioid mesothelioma patients with very long survival display defects in DNA repair","volume":"15","author":"Ganzinelli","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.critrevonc.2024.104481_bib54","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.2004088","article-title":"Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal","volume":"6","author":"Gao","year":"2013","journal-title":"Sci. Signal"},{"key":"10.1016\/j.critrevonc.2024.104481_bib55","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.pharmthera.2016.02.003","article-title":"DNA repair targeted therapy: the past or future of cancer treatment?","volume":"160","author":"Gavande","year":"2016","journal-title":"Pharm. Ther."},{"key":"10.1016\/j.critrevonc.2024.104481_bib56","doi-asserted-by":"crossref","unstructured":"T.J. George, J.-H. Lee, P.J. Hosein, D.L. DeRemer, J.A. Chatzkel, B.H. Ramnaraign, S.C. Rogers, M.J. Markham, K.C. Daily, N. Ezenwajiaku, D. Li, M.C. Murphy, A.J. Franke, S. Staal, J.L. Close, D.V. Jones, C.J. Allegra, Results of a phase II trial of the PARP inhibitor, niraparib, in BAP1 and other DNA damage response pathway deficient neoplasms., 40 (2022) 3122. https:\/\/doi.org\/10.1200\/JCO.2022.40.16_SUPPL.3122.","DOI":"10.1200\/JCO.2022.40.16_suppl.3122"},{"key":"10.1016\/j.critrevonc.2024.104481_bib57","doi-asserted-by":"crossref","unstructured":"H.Lal Goel, A.M. Mercurio, VEGF targets the tumour cell, (2013). https:\/\/doi.org\/10.1038\/nrc3627.","DOI":"10.1038\/nrc3627"},{"key":"10.1016\/j.critrevonc.2024.104481_bib58","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1158\/1535-7163.MCT-13-0926","article-title":"Anetumab ravtansine: a novel mesothelin-targeting antibody-drug conjugate cures tumors with heterogeneous target expression favored by bystander effect","volume":"13","author":"Golfier","year":"2014","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.critrevonc.2024.104481_bib59","doi-asserted-by":"crossref","unstructured":"Y. Goto, K. Shinjo, Y. Kondo, L. Shen, M. Toyota, H. Suzuki, W. Gao, B. An, M. Fujii, H. Murakami, H. Osada, T. Taniguchi, N. Usami, M. Kondo, Y. Hasegawa, K. Shimokata, K. Matsuo, T. Hida, N. Fujimoto, T. Kishimoto, J.-P.J. Issa, Y. Sekido, Epigenetic Profiles Distinguish Malignant Pleural Mesothelioma from Lung Adenocarcinoma, Pathobiology, and Genetics (n.d.). https:\/\/doi.org\/10.1158\/0008-5472.CAN-09-1595.","DOI":"10.1158\/0008-5472.CAN-09-1595"},{"key":"10.1016\/j.critrevonc.2024.104481_bib60","doi-asserted-by":"crossref","first-page":"3591","DOI":"10.1200\/JCO.2017.72.9012","article-title":"Nintedanib plus pemetrexed\/cisplatin in patients with malignant pleural mesothelioma: Phase II results from the randomized, placebo-controlled lume-meso trial","volume":"35","author":"Grosso","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2024.104481_bib61","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1158\/0008-5472.CAN-14-1008","article-title":"Whole-exome sequencing reveals frequent genetic alterations in BAP1, NF2, CDKN2A, and CUL1 in malignant pleural mesothelioma","volume":"75","author":"Guo","year":"2015","journal-title":"Cancer Res"},{"key":"10.1016\/j.critrevonc.2024.104481_bib62","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1158\/1078-0432.CCR-15-1623","article-title":"New life for immunotoxin cancer therapy","volume":"22","author":"Hassan","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2024.104481_bib63","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1200\/JCO.19.02085","article-title":"First-in-human, multicenter, phase i dose-escalation and expansion study of anti-mesothelin antibody-drug conjugate anetumab ravtansine in advanced or metastatic solid tumors","volume":"38","author":"Hassan","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2024.104481_bib64","doi-asserted-by":"crossref","first-page":"5144","DOI":"10.1158\/1078-0432.CCR-07-0869","article-title":"Phase I Study of SS1P, a recombinant anti-mesothelin immunotoxin given as a Bolus I.V. infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers","volume":"13","author":"Hassan","year":"2007","journal-title":"Clin. Cancer Res."},{"issue":"5","key":"10.1016\/j.critrevonc.2024.104481_bib65","article-title":"Major cancer regressions in mesothelioma after treatment with an anti-mesothelin immunotoxin and immune suppression","author":"Hassan","year":"2013","journal-title":"Sci. Transl. Med"},{"key":"10.1016\/j.critrevonc.2024.104481_bib66","doi-asserted-by":"crossref","first-page":"3311","DOI":"10.1002\/cncr.28875","volume":"120","author":"Hassan","year":"2014","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2024.104481_bib67","doi-asserted-by":"crossref","first-page":"4171","DOI":"10.1200\/JCO.2016.68.3672","article-title":"Mesothelin immunotherapy for cancer: Ready for prime time?","volume":"34","author":"Hassan","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2024.104481_bib68","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1038\/s41416-022-01979-0","article-title":"Genomic landscape of pleural and peritoneal mesothelioma tumours","volume":"127","author":"Hiltbrunner","year":"2022","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.critrevonc.2024.104481_bib69","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1158\/2159-8290.CD-18-0804","article-title":"Integrative molecular characterization of malignant pleural mesothelioma","volume":"8","author":"Hmeljak","year":"2018","journal-title":"Cancer Discov."},{"key":"10.1016\/j.critrevonc.2024.104481_bib70","doi-asserted-by":"crossref","first-page":"S830","DOI":"10.1016\/j.annonc.2021.08.1344","article-title":"959O Gavocabtagene autoleucel (gavo-cel, TC-210) dose escalation in refractory mesothelin-expressing solid tumors","volume":"32","author":"Hong","year":"2021","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2024.104481_bib71","doi-asserted-by":"crossref","DOI":"10.1177\/1753466620935770","article-title":"Acquired multiple mutations ALK I1171N, L1196M and G1202R mediate lorlatinib resistance in EML4-ALK-rearranged malignant pleural mesothelioma: a case report","volume":"14","author":"Hu","year":"2020","journal-title":"Ther. Adv. Respir. Dis."},{"key":"10.1016\/j.critrevonc.2024.104481_bib72","doi-asserted-by":"crossref","first-page":"89","DOI":"10.5858\/arpa.2017-0124-RA","article-title":"Guidelines for pathologic diagnosis of malignant mesothelioma 2017 update of the consensus statement from the International Mesothelioma Interest Group","volume":"142","author":"Husain","year":"2018","journal-title":"Arch. Pathol. Lab Med"},{"key":"10.1016\/j.critrevonc.2024.104481_bib73","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1038\/nature08467","article-title":"The DNA-damage response in human biology and disease","volume":"461","author":"Jackson","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2024.104481_bib74","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.lungcan.2011.11.014","article-title":"Vatalanib in malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B (CALGB 30107)","volume":"76","author":"Jahan","year":"2012","journal-title":"Lung Cancer"},{"key":"10.1016\/j.critrevonc.2024.104481_bib75","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1016\/j.athoracsur.2021.08.054","article-title":"Inhibition of cyclin dependent Kinase 4\/6 overcomes primary resistance to programmed cell death 1 blockade in malignant mesothelioma","volume":"114","author":"Jang","year":"2022","journal-title":"Ann. Thorac. Surg."},{"key":"10.1016\/j.critrevonc.2024.104481_bib76","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1016\/j.cellsig.2016.08.004","article-title":"The roles of the Hippo pathway in cancer metastasis","volume":"28","author":"Janse van Rensburg","year":"2016","journal-title":"Cell Signal"},{"key":"10.1016\/j.critrevonc.2024.104481_bib77","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/nrd4161","article-title":"The two faces of Hippo: targeting the Hippo pathway for regenerative medicine and cancer treatment","volume":"13","author":"Johnson","year":"2013","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.critrevonc.2024.104481_bib78","first-page":"4399","article-title":"The novel potent TEAD inhibitor, K-975, inhibits YAP1\/TAZ-TEAD protein-protein interactions and exerts an anti-tumor effect on malignant pleural mesothelioma","volume":"10","author":"Kaneda","year":"2020","journal-title":"Am. J. Cancer Res"},{"key":"10.1016\/j.critrevonc.2024.104481_bib79","doi-asserted-by":"crossref","first-page":"3923","DOI":"10.1200\/JCO.2005.14.167","article-title":"Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer","volume":"23","author":"Kelly","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2024.104481_bib80","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1200\/JCO.2011.41.5869","article-title":"Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine\/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma","volume":"30","author":"Kindler","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2024.104481_bib81","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/S1470-2045(22)00061-4","article-title":"Anetumab ravtansine versus vinorelbine in patients with relapsed, mesothelin-positive malignant pleural mesothelioma (ARCS-M): a randomised, open-label phase 2 trial","volume":"23","author":"Kindler","year":"2022","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2024.104481_bib82","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.juro.2007.03.109","article-title":"Down-regulation of HLA class I antigens in prostate cancer tissues and up-regulation by histone deacetylase inhibition","volume":"178","author":"Kitamura","year":"2007","journal-title":"J. Urol."},{"key":"10.1016\/j.critrevonc.2024.104481_bib83","doi-asserted-by":"crossref","first-page":"S745","DOI":"10.1016\/j.jtho.2018.08.1264","article-title":"P2.06-09 MiST3: a phase II study of oral selective AXL inhibitor bemcentinib (BGB324) in combination with pembrolizumab in pts with malignant mesothelioma","volume":"13","author":"Krebs","year":"2018","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.critrevonc.2024.104481_bib84","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/S1470-2045(15)70056-2","article-title":"Vorinostat in patients with advanced malignant pleural mesothelioma who have progressed on previous chemotherapy (VANTAGE-014): a phase 3, double-blind, randomised, placebo-controlled trial","volume":"16","author":"Krug","year":"2015","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2024.104481_bib85","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2010.05.002","article-title":"SnapShot: DNA mismatch repair","volume":"141","author":"Larrea","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.critrevonc.2024.104481_bib86","doi-asserted-by":"crossref","first-page":"587","DOI":"10.18632\/oncotarget.1782","article-title":"Immune regulation by low doses of the DNA methyltransferase inhibitor 5-azacitidine in common human epithelial cancers","volume":"5","author":"Li","year":"2014","journal-title":"Oncotarget"},{"key":"10.1016\/j.critrevonc.2024.104481_bib87","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1101\/gad.192856.112","article-title":"Genetic and pharmacological disruption of the TEAD\u2013YAP complex suppresses the oncogenic activity of YAP","volume":"26","author":"Liu-Chittenden","year":"2012","journal-title":"Genes Dev."},{"key":"10.1016\/j.critrevonc.2024.104481_bib88","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1097\/JTO.0000000000000436","article-title":"Targeted next-generation sequencing of cancer genes in advanced stage malignant pleural mesothelioma: a retrospective study","volume":"10","author":"Lo Iacono","year":"2015","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.critrevonc.2024.104481_bib89","doi-asserted-by":"crossref","first-page":"2502","DOI":"10.1158\/1078-0432.CCR-10-2745","article-title":"Phase I trial of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumors","volume":"17","author":"LoRusso","year":"2011","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.critrevonc.2024.104481_bib90","first-page":"1157","article-title":"Role of evaluating tumor-infiltrating lymphocytes, programmed death-1 ligand 1 and mismatch repair proteins expression in malignant mesothelioma","volume":"55","author":"Losi","year":"2019","journal-title":"Int J. Oncol."},{"key":"10.1016\/j.critrevonc.2024.104481_bib91","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1146\/annurev-biochem-013118-111829","article-title":"The hippo pathway: biology and pathophysiology","volume":"88","author":"Ma","year":"2019","journal-title":"Annu Rev. Biochem"},{"key":"10.1016\/j.critrevonc.2024.104481_bib92","doi-asserted-by":"crossref","first-page":"7017","DOI":"10.4049\/jimmunol.165.12.7017","article-title":"Activation of MHC class I, II, and CD40 gene expression by histone deacetylase inhibitors","volume":"165","author":"Magner","year":"2000","journal-title":"J. Immunol."},{"key":"10.1016\/j.critrevonc.2024.104481_bib93","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/s41416-019-0379-8","article-title":"MST1\/Hippo promoter gene methylation predicts poor survival in patients with malignant pleural mesothelioma in the IFCT-GFPC-0701 MAPS Phase 3 trial","volume":"120","author":"Maille","year":"2019","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.critrevonc.2024.104481_bib94","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1038\/s41416-019-0452-3","article-title":"A phase Ib dose-finding, pharmacokinetic study of the focal adhesion kinase inhibitor GSK2256098 and trametinib in patients with advanced solid tumours","volume":"120","author":"Mak","year":"2019","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.critrevonc.2024.104481_bib95","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/s41588-023-01321-1","article-title":"Multiomic analysis of malignant pleural mesothelioma identifies molecular axes and specialized tumor profiles driving intertumor heterogeneity","volume":"55","author":"Mangiante","year":"2023","journal-title":"Nat. Genet."},{"key":"10.1016\/j.critrevonc.2024.104481_bib96","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1158\/0008-5472.CAN-19-1633","article-title":"Combined MEK and PI3K\/p110\u03b2 Inhibition as a novel targeted therapy for malignant mesothelioma displaying sarcomatoid features","volume":"80","author":"Marques","year":"2020","journal-title":"Cancer Res"},{"key":"10.1016\/j.critrevonc.2024.104481_bib97","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1158\/1535-7163.MCT-15-0583","article-title":"Antagonizing the hedgehog pathway with vismodegib impairs malignant pleural mesothelioma growth in vivo by affecting stroma","volume":"15","author":"Meerang","year":"2016","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.critrevonc.2024.104481_bib98","doi-asserted-by":"crossref","first-page":"3460","DOI":"10.3390\/cancers12113460","article-title":"Importance of Cullin4 Ubiquitin Ligase in Malignant Pleural Mesothelioma","volume":"12","author":"Meerang","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.critrevonc.2024.104481_bib99","doi-asserted-by":"crossref","first-page":"20781","DOI":"10.18632\/oncotarget.25111","article-title":"A subgroup of pleural mesothelioma expresses ALK protein and may be targetable by combined rapamycin and crizotinib therapy","volume":"9","author":"M\u00f6nch","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.critrevonc.2024.104481_bib100","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/imr.12174","article-title":"Genetic and epigenetic basis of Treg cell development and function: from a FoxP3-centered view to an epigenome-defined view of natural Treg cells","volume":"259","author":"Morikawa","year":"2014","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.critrevonc.2024.104481_bib101","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1101\/gad.189601","article-title":"The NF2 tumor suppressor gene product, merlin, mediates contact inhibition of growth through interactions with CD44","volume":"15","author":"Morrison","year":"2001","journal-title":"Genes Dev."},{"key":"10.1016\/j.critrevonc.2024.104481_bib102","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1158\/0008-5472.CAN-10-2164","article-title":"LATS2 is a tumor suppressor gene of malignant mesothelioma","volume":"71","author":"Murakami","year":"2011","journal-title":"Cancer Res"},{"key":"10.1016\/j.critrevonc.2024.104481_bib103","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1097\/JTO.0b013e31825f22ee","article-title":"A phase II study of intermittent sunitinib malate as second-line therapy in progressive malignant pleural mesothelioma","volume":"7","author":"Nowak","year":"2012","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.critrevonc.2024.104481_bib104","doi-asserted-by":"crossref","first-page":"6357","DOI":"10.1038\/s41388-018-0405-y","article-title":"Differential regulation of the sphere formation and maintenance of cancer-initiating cells of malignant mesothelioma via CD44 and ALK4 signaling pathways","volume":"37","author":"Ohno","year":"2018","journal-title":"Oncogene"},{"key":"10.1016\/j.critrevonc.2024.104481_bib105","doi-asserted-by":"crossref","first-page":"5485","DOI":"10.1158\/1078-0432.CCR-19-0103","article-title":"Clinical efficacy and safety of nivolumab: results of a multicenter, Open-label, Single-arm, Japanese Phase II study in Malignant Pleural Mesothelioma (MERIT)","volume":"25","author":"Okada","year":"2019","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.critrevonc.2024.104481_bib106","doi-asserted-by":"crossref","first-page":"154","DOI":"10.3389\/fimmu.2015.00154","article-title":"CD44 acts as a signaling platform controlling tumor progression and metastasis","volume":"6","author":"Orian-Rousseau","year":"2015","journal-title":"Front. Immunol."},{"key":"10.1016\/j.critrevonc.2024.104481_bib107","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1097\/JTO.0000000000000360","article-title":"SWOG S0722: phase II study of mTOR inhibitor everolimus (RAD001) in advanced malignant pleural mesothelioma (MPM)","volume":"10","author":"Ou","year":"2015","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.critrevonc.2024.104481_bib108","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1200\/JCO.2018.78.5204","article-title":"Frequency of germline mutations in cancer susceptibility genes in malignant mesothelioma","volume":"36","author":"Panou","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2024.104481_bib109","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/j.jtho.2017.03.023","article-title":"A Novel BRCA1-Associated Protein-1 Isoform Affects Response of Mesothelioma Cells to Drugs Impairing BRCA1-Mediated DNA Repair","volume":"12","author":"Parrotta","year":"2017","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.critrevonc.2024.104481_bib110","doi-asserted-by":"crossref","unstructured":"F. Passiglia, L. Righi, P. Bironzo, A. List\u00ec, G. Farinea, E. Capelletto, S. Novello, A. Merlini, G.V. Scagliotti, Niraparib plus Dostarlimab in Pleural Mesothelioma or Non-Small Cell Lung Cancer harboring HRR mutations: interim results of the UNITO-001 phase 2 prospective trial., Clin Cancer Res (2023). \u3008https:\/\/doi.org\/10.1158\/1078-0432.CCR-23-2431\/731757\/NIRAPARIB-PLUS-DOSTARLIMAB-IN-PLEURAL-MESOTHELIOMA\u3009.","DOI":"10.1158\/1078-0432.25324517"},{"key":"10.1016\/j.critrevonc.2024.104481_bib111","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/nrc1891","article-title":"Immunotoxin therapy of cancer","volume":"6","author":"Pastan","year":"2006","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.critrevonc.2024.104481_bib112","doi-asserted-by":"crossref","unstructured":"M. Patel, A. Elliott, S.V. Liu, C. Kim, L.E. Raez, R. Feldman, S.G. Pai, A.J. Wozniak, M. Nagasaka, G. Lopes, A.I. Spira, E.S. Kim, W.M. Korn, H. Mamdani, Genomic landscape and immune phenotype of malignant pleural mesothelioma., 38 (2020) 9056\u20139056. \u3008https:\/\/doi.org\/10.1200\/JCO.2020.38.15_SUPPL.9056\u3009.","DOI":"10.1200\/JCO.2020.38.15_suppl.9056"},{"key":"10.1016\/j.critrevonc.2024.104481_bib113","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/nature15520","article-title":"Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy","volume":"527","author":"Peng","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2024.104481_bib114","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1007\/s11912-022-01302-3","article-title":"The evolving therapeutic landscape for malignant pleural mesothelioma","volume":"24","author":"Perera","year":"2022","journal-title":"Curr. Oncol. Rep."},{"key":"10.1016\/j.critrevonc.2024.104481_bib115","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-015-1363-1","article-title":"The combination of sorafenib and everolimus shows antitumor activity in preclinical models of malignant pleural mesothelioma","volume":"15","author":"Pignochino","year":"2015","journal-title":"BMC Cancer"},{"key":"10.1016\/j.critrevonc.2024.104481_bib116","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1016\/S1470-2045(21)00404-6","article-title":"Gemcitabine with or without ramucirumab as second-line treatment for malignant pleural mesothelioma (RAMES): a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"22","author":"Pinto","year":"2021","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2024.104481_bib117","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.annonc.2021.11.005","article-title":"Malignant pleural mesothelioma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up \u2606","volume":"33","author":"Popat","year":"2022","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2024.104481_bib118","doi-asserted-by":"crossref","unstructured":"S. Popat, E. Felip, U. Dafni, A. Pope, S.C. Perez, R.N.H. Shah, F. de Marinis, L.C. Smith, R.B. Caro, M. Fr\u00fch, K. Nackaerts, L. Greillier, A. Scherz, B. Massuti, S. Schaer, S.S. Prince, H. Roschitzki-Voser, B. Ruepp, S. Peters, R.A. Stahel, for the E. 13-18 B. Collaborators, BEAT-meso: A randomized phase III study of bevacizumab (B) and standard chemotherapy (C) with or without atezolizumab (A), as first-line treatment (TX) for advanced pleural mesothelioma (PM)\u2014Results from the ETOP 13-18 trial., 42 (2024) LBA8002\u2013LBA8002. \u3008https:\/\/doi.org\/10.1200\/JCO.2024.42.17_SUPPL.LBA8002\u3009.","DOI":"10.1200\/JCO.2024.42.17_suppl.LBA8002"},{"key":"10.1016\/j.critrevonc.2024.104481_bib119","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1200\/PO.20.00260","article-title":"Durable Response to Vismodegib in PTCH1 F1147fs mutant relapsed malignant pleural mesothelioma: implications for mesothelioma drug treatment","volume":"5","author":"Popat","year":"2021","journal-title":"JCO Precis Oncol."},{"key":"10.1016\/j.critrevonc.2024.104481_bib120","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.tcb.2019.10.005","article-title":"The hippo pathway, YAP\/TAZ, and the plasma membrane","volume":"30","author":"Rausch","year":"2020","journal-title":"Trends Cell Biol."},{"key":"10.1016\/j.critrevonc.2024.104481_bib121","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1038\/nrm.2017.53","article-title":"The multifaceted roles of PARP1 in DNA repair and chromatin remodelling","volume":"18","author":"Ray Chaudhuri","year":"2017","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.critrevonc.2024.104481_bib122","doi-asserted-by":"crossref","unstructured":"B.W.S. Robinson, R.A. Lake, Advances in Malignant Mesothelioma, 353 (2005) 1591\u20131603. https:\/\/doi.org\/10.1056\/NEJMRA050152.","DOI":"10.1056\/NEJMra050152"},{"key":"10.1016\/j.critrevonc.2024.104481_bib123","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1158\/1078-0432.CCR-13-1710","article-title":"A phase I, multicenter, open-label, first-in-human, dose-escalation study of the oral smoothened inhibitor Sonidegib (LDE225) in patients with advanced solid tumors","volume":"20","author":"Rodon","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2024.104481_bib124","doi-asserted-by":"crossref","first-page":"3218","DOI":"10.1016\/j.xphs.2019.06.012","article-title":"Synergistic Enhancement of Cellular Uptake With CD44-expressing malignant pleural mesothelioma by combining cationic liposome and hyaluronic acid\u2013lipid conjugate","volume":"108","author":"Sakurai","year":"2019","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.critrevonc.2024.104481_bib125","doi-asserted-by":"crossref","DOI":"10.1186\/s13046-022-02284-7","article-title":"SKP2 drives the sensitivity to neddylation inhibitors and cisplatin in malignant pleural mesothelioma","volume":"41","author":"Salaroglio","year":"2022","journal-title":"J. Exp. Clin. Cancer Res"},{"key":"10.1016\/j.critrevonc.2024.104481_bib126","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.cell.2018.03.035","article-title":"Oncogenic signaling pathways in the cancer genome atlas","volume":"173","author":"Sanchez-Vega","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.critrevonc.2024.104481_bib127","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222312868","article-title":"Correlation of MET-receptor overexpression with MET gene amplification and patient outcome in malignant mesothelioma","volume":"22","author":"Santoni-Rugiu","year":"2021","journal-title":"Int J. Mol. Sci."},{"key":"10.1016\/j.critrevonc.2024.104481_bib128","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/S2213-2600(19)30139-0","article-title":"Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME-Meso): a double-blind, randomised, placebo-controlled phase 3 trial","volume":"7","author":"Scagliotti","year":"2019","journal-title":"Lancet Respir. Med"},{"key":"10.1016\/j.critrevonc.2024.104481_bib129","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S1470-2045(18)30765-4","article-title":"Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial","volume":"20","author":"Scherpereel","year":"2019","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2024.104481_bib130","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1349-7006.2009.01336.x","article-title":"Genomic abnormalities and signal transduction dysregulation in malignant mesothelioma cells","volume":"101","author":"Sekido","year":"2010","journal-title":"Cancer Sci."},{"key":"10.1016\/j.critrevonc.2024.104481_bib131","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1093\/carcin\/bgt166","article-title":"Molecular pathogenesis of malignant mesothelioma","volume":"34","author":"Sekido","year":"2013","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.critrevonc.2024.104481_bib132","doi-asserted-by":"crossref","first-page":"18","DOI":"10.3389\/fcell.2017.00018","article-title":"CD44: A multifunctional cell surface adhesion receptor is a regulator of progression and metastasis of cancer cells","volume":"5","author":"Senbanjo","year":"2017","journal-title":"Front.Cell Dev. Biol."},{"key":"10.1016\/j.critrevonc.2024.104481_bib133","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3008639","article-title":"Merlin deficiency predicts FAK inhibitor sensitivity: A synthetic lethal relationship","volume":"6","author":"Shapiro","year":"2014","journal-title":"Sci. Transl. Med"},{"key":"10.1016\/j.critrevonc.2024.104481_bib134","doi-asserted-by":"crossref","first-page":"4646","DOI":"10.1158\/1078-0432.CCR-12-0599","article-title":"Role of hedgehog signaling in malignant pleural mesothelioma","volume":"18","author":"Shi","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2024.104481_bib135","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1002\/1878-0261.12498","article-title":"New insights into YAP\/TAZ nucleo-cytoplasmic shuttling: new cancer therapeutic opportunities?","volume":"13","author":"Shreberk-Shaked","year":"2019","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.critrevonc.2024.104481_bib136","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.pharmthera.2013.12.015","article-title":"Epigenetic drugs as immunomodulators for combination therapies in solid tumors","volume":"142","author":"Sigalotti","year":"2014","journal-title":"Pharm. Ther."},{"key":"10.1016\/j.critrevonc.2024.104481_bib137","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.21037\/tlcr-19-425","article-title":"SMO mutations confer poor prognosis in malignant pleural mesothelioma","volume":"9","author":"Signorelli","year":"2020","journal-title":"Transl. Lung Cancer Res"},{"key":"10.1016\/j.critrevonc.2024.104481_bib138","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.omtn.2021.04.001","article-title":"MicroRNA-206 suppresses mesothelioma progression via the Ras signaling axis","volume":"24","author":"Singh","year":"2021","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.critrevonc.2024.104481_bib139","doi-asserted-by":"crossref","first-page":"3046","DOI":"10.1158\/0008-5472.CAN-19-3853","article-title":"Targeting hippo-dependent and hippo-independent YAP1 signaling for the treatment of childhood rhabdomyosarcoma","volume":"80","author":"Slemmons","year":"2020","journal-title":"Cancer Res"},{"key":"10.1016\/j.critrevonc.2024.104481_bib140","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/cancers12102757","article-title":"AXL inactivation inhibits mesothelioma growth and migration via regulation of p53 expression","volume":"12","author":"Song","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.critrevonc.2024.104481_bib141","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1093\/annonc\/mdw427","article-title":"A phase I, pharmacokinetic and pharmacodynamic study of GSK2256098, a focal adhesion kinase inhibitor, in patients with advanced solid tumors","volume":"27","author":"Soria","year":"2016","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2024.104481_bib142","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.ejca.2008.01.003","article-title":"Role of homologous recombination in trabectedin-induced DNA damage","volume":"44","author":"Tavecchio","year":"2008","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.critrevonc.2024.104481_bib143","doi-asserted-by":"crossref","first-page":"5925","DOI":"10.3390\/cancers14235925","article-title":"CDK4\/6 inhibition enhances the efficacy of standard chemotherapy treatment in malignant pleural mesothelioma cells","volume":"14","author":"Terenziani","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.critrevonc.2024.104481_bib144","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.canlet.2011.08.021","article-title":"DNA repair systems in malignant mesothelioma","volume":"312","author":"Toumpanakis","year":"2011","journal-title":"Cancer Lett."},{"key":"10.1016\/j.critrevonc.2024.104481_bib145","doi-asserted-by":"crossref","first-page":"3191","DOI":"10.1158\/1078-0432.CCR-16-1971","article-title":"Co-occurring mutations of tumor suppressor genes, LATS2 and NF2, in malignant pleural mesothelioma","volume":"23","author":"Tranchant","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2024.104481_bib146","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1200\/JCO.19.00269","article-title":"Phase II trial of cediranib in combination with cisplatin and pemetrexed in chemotherapy-na\u00efve patients with unresectable malignant pleural mesothelioma (SWOG S0905)","volume":"37","author":"Tsao","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2024.104481_bib147","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1002\/(SICI)1097-0142(19970601)79:11<2237::AID-CNCR23>3.0.CO;2-W","article-title":"Dihydro-5-azacytidine in malignant mesothelioma a phase II trial demonstrating activity accompanied by cardiac toxicity","volume":"79","author":"Vogelzang","year":"1997","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2024.104481_bib148","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"Vogelzang","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2024.104481_bib149","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s00262-016-1935-1","article-title":"Histone deacetylase inhibitors deplete myeloid-derived suppressor cells induced by 4T1 mammary tumors in vivo and in vitro","volume":"66","author":"Wang","year":"2017","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.critrevonc.2024.104481_bib150","doi-asserted-by":"crossref","first-page":"2646","DOI":"10.1002\/cam4.1179","article-title":"Novel ATP-competitive Akt inhibitor afuresertib suppresses the proliferation of malignant pleural mesothelioma cells","volume":"6","author":"Yamaji","year":"2017","journal-title":"Cancer Med"},{"key":"10.1016\/j.critrevonc.2024.104481_bib151","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1097\/JTO.0b013e3181d2f008","article-title":"Clinical significance of serum vascular endothelial growth factor in malignant pleural mesothelioma","volume":"5","author":"Yasumitsu","year":"2010","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.critrevonc.2024.104481_bib152","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.jtcvs.2013.08.035","article-title":"Targeting of the Hedgehog signal transduction pathway suppresses survival of malignant pleural mesothelioma cells in vitro","volume":"147","author":"You","year":"2014","journal-title":"J. Thorac. Cardiovasc Surg."},{"key":"10.1016\/j.critrevonc.2024.104481_bib153","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/S0140-6736(15)01238-6","article-title":"Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial","volume":"387","author":"Zalcman","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2024.104481_bib154","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1007\/s10637-021-01086-6","article-title":"Phase 1 cohort expansion study of LY3023414, a dual PI3K\/mTOR inhibitor, in patients with advanced mesothelioma","volume":"39","author":"Zauderer","year":"2021","journal-title":"Invest N. Drugs"},{"key":"10.1016\/j.critrevonc.2024.104481_bib155","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/S1470-2045(22)00277-7","article-title":"EZH2 inhibitor tazemetostat in patients with relapsed or refractory, BAP1-inactivated malignant pleural mesothelioma: a multicentre, open-label, phase 2 study","volume":"23","author":"Zauderer","year":"2022","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2024.104481_bib156","doi-asserted-by":"crossref","DOI":"10.1186\/1756-9966-32-7","article-title":"SMO expression level correlates with overall survival in patients with malignant pleural mesothelioma","volume":"32","author":"Zhang","year":"2013","journal-title":"J. Exp. Clin. Cancer Res"},{"key":"10.1016\/j.critrevonc.2024.104481_bib157","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1007\/s11095-013-1231-0","article-title":"The narrow-spectrum HDAC inhibitor entinostat enhances NKG2D expression without NK cell toxicity, leading to enhanced recognition of cancer cells","volume":"32","author":"Zhu","year":"2015","journal-title":"Pharm. Res"}],"updated-by":[{"DOI":"10.1016\/j.critrevonc.2024.104521","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000}}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842824002245?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842824002245?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,4]],"date-time":"2024-12-04T13:01:43Z","timestamp":1733317303000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842824002245"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":157,"alternative-id":["S1040842824002245"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2024.104481","relation":{"erratum":[{"id-type":"doi","id":"10.1016\/j.critrevonc.2024.104521","asserted-by":"object"}]},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Unleashing precision: A review of targeted approaches in pleural mesothelioma","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2024.104481","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"104481"}}